Abstract Number: 2121 • 2014 ACR/ARHP Annual Meeting
Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease
Background/Purpose Gout flare prevention relies heavily on urate-lowering therapies (ULT) such as allopurinol (ALP) and febuxostat (FBX) but clinical decision-making in patients with moderate to…Abstract Number: 2122 • 2014 ACR/ARHP Annual Meeting
Variation in the Prescribing Practices of Biologic Dmards
Background/Purpose: Biologic DMARDs (bDMARDs) are effective yet expensive treatments for RA. Variability in the prescribing practices of rheumatologists using these agents may be attributable to…Abstract Number: 2123 • 2014 ACR/ARHP Annual Meeting
Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis
Background/Purpose: Biologic drugs can be obtained both through Medicare's Part B medical benefit (physician administered drugs) or Part D pharmacy benefit (self-administered drugs). Coverage for…Abstract Number: 2124 • 2014 ACR/ARHP Annual Meeting
Characteristics of Medicare Beneficiaries Travelling Long Distances to Visit a Rheumatologist
Background/Purpose: Studies of the distribution of rheumatologists across the United States suggest that a significant number of patients travel long distances to visit a rheumatologist. …Abstract Number: 2125 • 2014 ACR/ARHP Annual Meeting
Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study
Background/Purpose: Refractory gouty arthritis (RGA) is a condition characterized by appearance of recurrent flares and contraindication, intolerance, or lack of efficacy to first-line anti-inflammatory therapy…Abstract Number: 2126 • 2014 ACR/ARHP Annual Meeting
The Utility of Digital Activity Fluorescence Optical Imaging in Quantifying Hand and Wrist Inflammation in Rheumatic Diseases
Background/Purpose The objective detection and quantification of disease activity in its earliest pathophysiological stage is critical for achieving optimal therapy results. Fluorescence optical imaging (FOI)…Abstract Number: 2127 • 2014 ACR/ARHP Annual Meeting
Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission
Background/Purpose: Recurrent flares in RA patients in complete remission (CR) are not an uncommon phenomenon. Studies with advanced imaging techniques have suggested that residual subclinical…Abstract Number: 2128 • 2014 ACR/ARHP Annual Meeting
Effectiveness of 18f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia-like Illness
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that affects the elderly. It is characterized by pain and stiffness in the shoulder and pelvic girdles. …Abstract Number: 2129 • 2014 ACR/ARHP Annual Meeting
Sensitivity and Specificity of the “Green Nail” Sign in Fluorescence Optical Imaging in Psoriatic Arthritis
Background/Purpose ICG-enhanced fluorescence optical imaging (FOI) is a novel technology for the assessment of inflammation in arthritis [1,2]. Recent work suggested that a “green nail”…Abstract Number: 2105 • 2014 ACR/ARHP Annual Meeting
Nonsurgical Treatment Patterns in Patients with Chronic Spinal Cord Injury
Background/Purpose: Sublesional loss of bone mineral density is a common complication in patients with chronic spinal cord injury (SCI) putting them at high risk for…Abstract Number: 2104 • 2014 ACR/ARHP Annual Meeting
Effectiveness of a Workplace Integrated Care Intervention on Work Productivity in Workers with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease with a profound impact on a person’s working life. Besides permanent work disability and sick leave,…Abstract Number: 2103 • 2014 ACR/ARHP Annual Meeting
Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical Functioning, Quality of Life and Resource Use Among RA Patients in a Clinical Practice Setting
Background/Purpose: Guidelines in RA recommend that treatment should be aimed at reaching a target of remission or low disease activity (LDA) as soon as possible,…Abstract Number: 2102 • 2014 ACR/ARHP Annual Meeting
A Tissue-Specific Lincrna in the TRAF1-C5 Risk Locus As a Putative Cis-Regulator, Bridging Genetics and Disease
Background/Purpose In the last decade genome wide association studies (GWAS) have identified genetic polymorphisms that associate with Rheumatoid arthritis (RA). However, the way these genetic…Abstract Number: 2101 • 2014 ACR/ARHP Annual Meeting
Epigenetic Study of Advanced Ankylosis in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory spinal disease characterized by ankylosis of the spine. A subset of patients develops significant ankylosis resulting in mobility…Abstract Number: 2100 • 2014 ACR/ARHP Annual Meeting
Activation of NFkβ Pathways in Sjögren’s Syndrome Related Lymphomagenesis-Role of the His159Tyr Mutation of the BAFF-R Receptor
Background/Purpose: Sjögren’s Syndrome (SS) bears the highest risk for lymphoma development among all autoimmune diseases. A growing body of evidence suggests activation of NFκB pathways…
